Europe Neurostimulation Devices Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User

The Europe neurostimulation devices market was valued at US$1.71 billion in 2022 and is expected to reach US$3.45 billion by 2030; it is estimated to register a CAGR of 9.1% from 2022 to 2030.

Rising Cases of Spinal Cord Injury Fuel Europe Neurostimulation Devices Market

The neurostimulation devices industry has gained traction owing to the rising elderly population prone to various spinal disorders. These population is becoming more susceptible to developing spinal disorders such as degenerative disc diseases, osteoarthritis, scoliosis, spinal tumor, and spinal stenosis. As this population ages, the natural wear and tear of the spine can lead to several spinal disorders. Hence, with this fact, the aging population poses a unique challenge to spine surgeons due to multiple increased frailty, medical comorbidities, decreased nutritional status, and the higher probability of postoperative complications. According to the World Health Organization (WHO) data published in October 2022, approximately 80% of the elderly population will be living in low-and middle-income countries by 2050, and it is anticipated that the pace of this population aging will be much faster than in the past. The aging demographic, coupled with lifestyle-related factors has led to a substantial increase in individuals experiencing spinal issues such as degenerative disc disease and spinal deformities. Therefore, high incidence of spinal cord injuries in old age and adults stimulates the demand for neurostimulation devices.

Europe Neurostimulation Devices Market Overview

The Europe neurostimulation devices market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The regional market is expected to grow significantly in the coming years owing to the rising prevalence of neurologic disorders such as cerebral aneurysms, stroke, and others and increasing product innovations made by the market players operating in the region. The market growth is also attributed to the development of healthcare systems in countries such as Germany, France, and Spain and rise in innovative product launches by key regional companies. In June 2020, Medtronic announced the launch of the PerceptTM PC Neurostimulator with BrainsenseTM technology. The technology simultaneously records and delivers electrical stimulations to the brain to relieve symptoms of Parkinson's disease (PD).

Europe Neurostimulation Devices Market Segmentation

The Europe neurostimulation devices market is segmented based on product, application, end user, and country.

Based on product, the Europe neurostimulation devices market is segmented into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and others. The spinal cord stimulator segment held the largest market share in 2022.

In terms of application, the Europe neurostimulation devices market is categorized into pain management, epilepsy, urinary and fecal incontinence, Parkinson's disease, and others. The pain management segment held the largest market share in 2022.

By end user, the Europe neurostimulation devices market is segmented into hospitals, specialty clinics, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Europe neurostimulation devices market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe neurostimulation devices market share in 2022.

Medtronic Plc, Boston Scientific Corp, Abbott Laboratories, Nevro Corp, LivaNova Plc, Synapse Biomedical Inc, ElectroCore Inc, and Mainstay Medical are some of the leading companies operating in the Europe neurostimulation devices market.